MicroRNA and transcription factor mediated regulatory network for ovarian cancer: Regulatory network of ovarian cancer

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 3219-3225

  Ying, Huanchun ^a   Lv, Jing ^b   Ying, Tianshu ^a   Li, Jun ^a   Yang, Qing ^a   Ma, Yuan ^c  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The Fifth People's Hospital of Shenyang   (China)

^c Anyang Tumor Hospital   (China)

Author keywords

Differentially expressed genes; Interaction network; MicroRNA; Ovarian cancer; Target genes; Transcription factor

Indexed keywords

EID: 84885420795     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0892-y     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. doi: 10.3322/caac.20006caac.20006.
2. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295-303. doi: 10.1001/jama.2011.766305/22/229.
3. Chou J, Werb Z. MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer Discov. 2012;2(12):1078-80. doi: 10.1158/2159-8290.
4. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 2010;42(8):1282-90. doi: 10.1016/j.
5. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186-99. doi: 10.1016/.
6. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2):e24. doi: 10.1371/journal.pmed.100002408-PLME-RA- 1271.
7. Llaurado M, Abal M, Castellvi J, Cabrera S, Gil-Moreno A, Perez-Benavente A, et al. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer. 2012;130(7):1532-43. doi: 10.1002/ijc.26148.
8. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116(1):117-25. doi: 10.1016/j.
9. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010;10:89. doi: 10.1186/1471-2407-10-89.
10. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer. 2010;10(5):371-8. doi: 10.1038/nrc2831nrc2831.
11. Trevino LS, Giles JR, Wang W, Urick ME, Johnson PA. Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin? Horm Cancer. 2010;1(4):177-86. doi: 10.1007/s12672-010-0024-8.
12. Wu J, Xie X, Liu Y, He J, Benitez R, Buckanovich RJ, et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J Proteome Res. 2012;11(9):4541-52. doi: 10.1021/pr300330z.
13. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-8. doi: 10.1038/ nature07385nature07385.
14. Yao C, Li H, Shen X, He Z, He L, Guo Z. Reproducibility and concordance of differential DNA methylation and gene expression in cancer. PLoS One. 2012;7(1):e29686. doi: 10.1371/journal.pone.0029686PONE-D-11-16562.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Soc Series B (Methodological). 1995;57:289-300.
16. Huangda W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57. doi: 10.1038/nprot.2008.211.
17. Fu J, Tang W, Du P, Wang G, Chen W, Li J, et al. Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol. 2012;6:68. doi: 10.1186/1752-0509-6-681752-0509-6-68.
18. Yu J, Cai X, He J, Zhao W, Wang Q, Liu B. Microarray-based analysis of gene regulation by transcription factors and microRNAs in glioma. Neurol Sci. 2012. doi: 10.1007/s10072-012-1228-1.
19. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, et al. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res. 2007;13(1):144-51. doi: 10.1158/1078-0432.CCR-06-0780.
20. Valle BL, D'Souza T, Becker KG, Wood III WH, Zhang Y, Wersto RP, et al. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One. 2013;8(4):e61836.
21. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001;414(6862):457-62. doi: 10.1038/3510659335106593.
22. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365(6444):349-52. doi: 10.1038/365349a0.
23. de Resende MF, Vieira S, Chinen LTD, Chiappelli F, da Fonseca FP, Guimarães GC, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):1-9.
24. Zhou B, Yuan T, Liu M, Liu H, Xie J, Shen Y, et al. Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer. Oncol Rep. 2012;28(4):1263-8.
25. Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 2012;12(1):321.
26. Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T, et al. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011;6(1):e16138. doi: 10.1371/journal.pone.0016138.
27. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135-43. doi: 10.1074/jbc.M608939200.
28. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11(7):847-62.
29. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000;97(16):9042-6. doi: 10.1073/pnas.
30. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118(12):3943-53. doi: 10.1172/JCI3715637156.
31. Yu JH, Zhu B-M, Wickre M, Riedlinger G, Chen W, Hosui A, et al. The transcription factors STAT5A and STAT5B negatively regulate cell proliferation through the activation of Cdkn2b and Cdkn1a expression. Hepatology (Baltimore, Md). 2010;52(5):1808.
32. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68(20):8191-4. doi: 10.1158/0008-5472.
33. Gibcus JH, Kroesen BJ, Koster R, Halsema N, de Jong D, de Jong S, et al. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. J Pathol. 2011;225(4):609-17.
34. Wang F, Fu XD, Zhou Y, Zhang Y. Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep. 2009;42(11):725-30.
35. Guo X, Hartley RS. Hur contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006;66(16):7948-56. doi: 10.1158/0008-5472. CAN-05-4362.
36. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995;92(26):12146-50.
37. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009;69(23):9090-5.
38. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008;36(16):5391-404.